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Abstract (up to 250 words): 
Antimicrobial resistance (AMR) poses a serious threat to global public health. Yet vaccinations 
have been largely undervalued as a method to hinder AMR progression. This study examined 
the AMR impact of increasing pneumococcal conjugate vaccine (PCV) coverage in China. 
China has one of the world’s highest rates of antibiotic use and low PCV coverage. We 
developed an agent-based DREAMR (Dynamic Representation of the Economics of AMR) 
model to examine the health and economic benefits of slowing AMR against commonly used 
antibiotics. We simulated PCV coverage, pneumococcal infections, antibiotic use, and AMR 
accumulation. Four antibiotics to treat pneumococcal diseases (penicillin, amoxicillin, 3rd 
generation cephalosporins, and meropenem) were modeled with antibiotic utilization, 
pharmacokinetics, and pharmacodynamics factored into predicting AMR accumulation. Three 
PCV coverage scenarios were simulated over five years: (1) status quo with no change in 
coverage, (2) scaled coverage increase to 99% in 5 years, and (3) accelerated coverage 
increase to 85% over 2 years followed by 3 years to reach 99% coverage. Compared to the 
status quo, we found that AMR against penicillin, amoxicillin, and 3rd generation cephalosporins 
was significantly reduced by 1.74%, 19.19%, and 14.87% in the scaled scenario and by 2.87%, 
29.97%, and 23.35% in the accelerated scenario. Cumulative costs due to AMR, including direct 
and indirect costs to patients and caretakers, were reduced by $2.76 billion in the scaled and 
$4.46 billion in the accelerated scenarios compared to the status quo. AMR benefits of vaccines 
are essential to quantify in order to drive appropriate investment.  
 
 
Significance Statement (up to 120 words) 
Vaccines are currently undervalued as few studies include vaccines’ value in hindering 
antimicrobial resistance (AMR). Pneumococcal infections pose a major threat to public health, 
which is preventable by the pneumococcal conjugate vaccine (PCV). China has high antibiotic 
use and low PCV coverage, making it an important country to assess resource allocations to 
address AMR. We developed an agent-based model to simulate the impact of increased PCV 
coverage on AMR accumulation. This study is the first to demonstrate the broader economic 
value of pneumococcal vaccination in slowing the development of AMR in China. Introducing 
PCV in China’s national immunization program would not only save lives but also bring wider 




The rapid rise in antimicrobial resistance (AMR) is a healthcare emergency (1). It threatens the 
prevention of infectious diseases and the efficacy of treatment options, leading to worse patient 
outcomes and resulting deaths. A 2014 study estimates that 700,000 deaths per year are 
attributable to AMR, which is projected to grow to 10 million deaths by 2050, costing up to 
US$100 trillion (2). Vaccination is a solution that can contribute to slowing the pace of AMR. 
Vaccinations can hinder AMR progression by reducing the incidence of sensitive and resistant 
infections (1). Vaccinations can also decrease disease incidence and the need for antibiotic use, 
reducing the selection and pressure for resistance to accumulate (3). Resistance to vaccines is 
unlikely compared to drugs because vaccines are inherently used prophylactically and combat 
pathogens through multiple pathways (4). Despite a growing recognition that vaccines can 
deliver AMR benefits, vaccines’ AMR-related value is not incorporated in most studies, 
leading to undervaluation and underinvestment (5). 
 
The pneumococcal conjugate vaccine (PCV), covering up to 13 different serotypes of 
Streptococcus pneumoniae (SP), has demonstrated that AMR benefits are possible. Previous 
studies in the US, Europe, and Africa have shown that PCV introduction has led to reduction in 
antibiotic use and decreased resistant invasive disease episodes (6). A 2016 study estimated 
that universal coverage with PCV could avert 11.4 million days per year of antibiotic use in 
children under five years of age (7). However, these AMR benefits of PCV have not been shown 
at the country level related to specific vaccination policies in order to have policy-makers 
incorporate PCV’s AMR-related value in decision making.  
 
China has one of the highest burden of childhood pneumonia cases caused by SP at around 
454,000 new episodes per year (8). SP is a major cause of morbidity and mortality in China, 
especially among children under five (9). The World Health Organization estimates that China 
accounts for 12% of SP infections and 3.6% of SP deaths worldwide in children under five (10). 
China’s Expanded Program on Immunization (EPI) currently does not include PCV among its 
mandatory vaccines available for free for registered children (11). The most recent data on PCV 
coverage among children in China was only at 4.7% in 2014 (12). Antibiotic use and misuse are 
also widespread in China, both within healthcare and animal agriculture systems (13, 14). In 
healthcare, Chinese patients often view antibiotics as a panacea, asking for antibiotics from 
providers even when unwarranted (15). For example, a 2014 Chinese national survey showed 
that 52.9% of out-patient visits resulted in antibiotic prescriptions, while only 39.4% of patients 
required them based on their clinical conditions (16). China's high burden of pneumococcal 
disease, low PCV coverage, and high antibiotic utilization makes it an important country to 
demonstrate the AMR-related value of pneumococcal vaccination.   
 
This study examined the health and economic impact of increasing PCV coverage in China, 
focusing on the value of PCV in slowing AMR progression. This research responds to calls for a 
global coordinated effort to conduct research on AMR-sensitive evaluations and integrated AMR 
strategies (1, 5, 7). We developed and utilize an agent-based model to simulate PCV coverage, 
pneumococcal infections, antibiotic use, AMR accumulation, and resulting health and economic 
outcomes. To our knowledge, this work is the first to demonstrate the broader economic value 




We developed an agent-based micro-simulation model known as Dynamic Representation of 
the Economics of Anti-Microbial Resistance (DREAMR) (17). The model has two interactive 
components, the human and bacteria sub-models (Figure 1). The human sub-model simulates 
the progression of healthcare seeking and treatment if a child were to become infected by SP. 
This includes probabilities for whether or not a child seeks care and at what type of health 
facility, whether a child receives outpatient or inpatient care, and what antibiotics are used for 
treatment. When antibiotics are utilized, the human sub-model interacts with the bacteria sub-
model, where bacteria may die, or survive and replicate, depending on the antibiotic’s 
pharmacokinetics and pharmacodynamics properties and the degree of exposure. The change 
in ratio between resistant and susceptible bacteria, known as the AMR ratio, subsequently 
influences pneumococcal disease treatment outcomes in the human sub-model. This model 
was developed in NetLogo 6.0.2, a free and accessible software with a multi-agent 
programmable modeling environment (18). All model inputs are presented in Table 1. Details of 
the model simulations are described below. 
 
Human Sub-model: Vaccination, Care-seeking and Treatment 
The DREAMR human sub-model simulated 8,000 agents, where each agent represented ten 
children, comprising a population of 80,000 children between zero and five years of age. 
Results were scaled to the pediatric population size in China based on the most current 
demographic data (19). Each agent in the model was assigned a PCV vaccination status based 
on coverage data available from the National Immunization Program Information System in 
China (12). Published literature were utilized to simulate PCV vaccine efficacy (20). The model 
incorporated effects of herd immunity, where immunized individuals provided protection among 
the unvaccinated population (21, 22). This study assumed herd immunity occurred at 85% PCV 
vaccination coverage, where decreased age-specific disease incidence rates were applied to  
simulate the indirect effect of immunization (23, 24). 
 
Modeled child agents faced an incidence of contracting pneumococcal infections, resulting in 
pneumococcal pneumonia, pneumococcal meningitis, or pneumococcal acute otitis media 
(AOM). Disease incidence rates for each condition were derived from the China Health 
Insurance and Research Association (CHIRA) database (25). Care seeking and treatment of 
pneumococcal disease were modeled separately for rural and urban environments (26). Child 
agents sought or did not seek care from healthcare facilities based on care-seeking rates from 
the literature (27, 28). Child agents who sought healthcare received treatment from one of the 
following levels of health facilities: (1) municipal level, (2) county level, (3) township/village level, 
or (4) private clinics (29). Child agents who did not seek care either self-medicated or remained 
untreated based on care-seeking rates from the Analysis Report of National Health Services 
Survey in China (30). Untreated agents faced a greater propensity to develop adverse health 
outcomes (i.e., disability and death) compared to those who received treatment (31). All children 
with acute otitis media were treated as outpatients, while all meningitis cases were treated as 
inpatients (32). Health facility-level specific hospitalization rates from the literature were applied 
to pneumococcal pneumonia cases who sought care (29). Antibiotic regimens and treatment 
durations for each pneumococcal disease were extracted from literature (33-39). Antibiotic 
utilization was simulated based on recommended doses and intervals (33, 34). The proportion 
of child agents treated with antibiotics for pneumococcal disease in the human sub-model 
affected the degree of antibiotic exposure in the bacteria sub-model.  
 
Bacteria Sub-model 
The DREAMR bacteria sub-model focused on four antibiotics commonly used to treat 
pneumococcal diseases in China: penicillin, amoxicillin, 3rd generation cephalosporins, and 
meropenem. We simulated 120,000 bacteria agents, 30,000 per antibiotic, where each bacteria 
were classified as either resistant or susceptible. The initial AMR ratios for antibiotics were 
determined based on the resistance patterns in China (38, 40-43). Bacteria agents were also 
assigned a minimum inhibitory concentration (MIC) from a gamma distribution based on the 
antibiotic and resistance status (44, 45). The method of moments approach was used to obtain 
parameters needed for the gamma distribution to characterize these distributions (46). The 
susceptibility breakpoint was set to be equal to that of the Clinical Laboratory Standards 
Institute, at the 90th percentile of the MIC gamma distribution (45). 
 
Pharmacokinetics and pharmacodynamics were used to determine which bacteria agents would 
die under antibiotic exposure. Pharmacokinetic characteristics, including the volume of 
distribution, total body clearance, and elimination rate constants were retrieved from literature 
and the product information for each antibiotic (47-53). The probability that bacteria encountered 
antibiotic exposure depended both on defined daily doses (DDDs) and the proportion of children 
colonized with SP (54). DDDs were obtained from the human sub-model, which measured the 
proportion of child agents using antibiotics for pneumococcal diseases. DDDs were then divided 
by the percentage of children colonized to estimate the probability that bacterial agents would 
be exposed to antibiotics. Large DDDs led to a larger probability for antibiotic exposure (55). 
Since all four antibiotics are time-dependent, we then estimated the percentage of time that 
exposed antibiotic concentrations were above MIC for each bacterium, which is based on the 
dose, dosing interval, MIC value, and pharmacokinetics of the antibiotic (56, 57). A bacterium 
agent would die once the percentage of time it was exposed to antibiotics above its MIC value 
became greater than the threshold of 50% (56, 58, 59). Susceptible strains of bacteria faced a 
higher probability of being killed compared to resistant strains due to a lower MIC distribution. 
Resistant bacteria also faced a fitness cost as they are often less fit to compete for resources 
and experienced a lowered probability of survival (60). Killed bacteria agents were replaced by 
replication of susceptible and resistant bacteria agents maintaining the latest AMR ratio.   
 
Human Sub-model: Health and Economic Outcomes 
The AMR ratio from the bacteria sub-model subsequently set the proportion of treatment failures 
in the human sub-model (61). Child agents with treatment failures from first-line antibiotics 
switched to second-line therapy, and overall treatment durations were prolonged. Child agents 
who self-medicated and experienced treatment failure sought care from formal health facilities. 
Patients either died or recovered from the disease episode based on case-fatality rates from the 
literature (62). Agents who survived from meningitis and AOM also faced a probability of 
developing long-term sequelae (35, 63). We simulated the number of cases, deaths, disabilities, 
average DDD, AMR ratios, cumulative treatments, and treatment failures over time.  
 
Economic outcomes were also assessed by using the cost-of-illness method, estimating related 
direct medical costs, direct-non-medical costs, productivity losses for caregivers, and 
productivity losses due to death/disability (29, 64-66). Direct medical and non-medical costs to 
treat pneumococcal disease at different health facility levels in China were abstracted from the 
literature (29, 66). Productivity losses were estimated based on China’s GDP per capita per day 
and the duration of lost productivity (67, 68). Caregivers lost income over the duration of illness, 
and children who died or became disabled lost productivity from age 15 until average age of 
retirement at 60. Productivity loss for children who lived with a disability due to meningitis was 
reduced by the relevant disability-adjusted life year (DALY) weight (69, 70). All costs are 
presented in US dollars (2019). 
 
Scenario and Sensitivity Analyses 
Simulations were run over 5 years from 2020 to 2025. Three scenarios of PCV vaccination 
coverage were modeled. The first scenario simulated the status quo, where PCV coverage 
remained at current levels (4.74%) over five years. The second “Scaled” scenario linearly 
increased PCV coverage from status quo to 99% over five years. We scaled PCV coverage to 
99% based on China’s nationally reported immunization coverage rates for other childhood 
vaccines. In the third “Accelerated” scenario, PCV coverage increased linearly from status quo 
to 85% in the first two years, and to 99% over the next three years. This was designed to 
simulate the adoption of PCV in China’s EPI program to quickly reach 85% coverage. Our 
results compare the scaled and accelerated scenarios to status quo. 
 
Sensitivity analyses were conducted to obtain uncertainty ranges around key outcomes. 
Uncertainty arising from various procedures in the DREAMR agent-based model were 
minimized by averaging all results across 5,000 simulations. Moreover, uncertainty in model 
inputs were incorporated though a probabilistic sensitivity analysis (PSA) where key input 
values were randomly drawn from underlying distributions based on means and standard errors 




The impact of PCV in reducing pneumococcal disease burden are shown in Table 2. Based on 
current PCV coverage, we estimated that China has 70.8 million cases of pneumococcal 
pneumonia, 2,800 cases of pneumococcal meningitis, and 62.2 million cases of pneumococcal 
AOM over 5 years. Compared to the status quo, the scaled scenario reduced the disease 
burden of pneumococcal pneumonia to 65.1 million cases (8.1% decrease), pneumococcal 
meningitis to 2,100 cases (25.3% decrease), and pneumococcal AOM to 59.3 million cases 
(4.7% decrease). The accelerated scenario further reduced the disease burden of 
pneumococcal pneumonia to 61.4 million cases (13.3% decrease), pneumococcal meningitis to 
1,700 cases (38.7% decrease), and pneumococcal AOM to 57.7 million cases (7.2% decrease). 
While the status quo scenario estimated 1.4 million deaths from pneumococcal diseases over 5 
years, the scaled and accelerated scenarios reduced the number of overall deaths to 1.3 million 
(8.1% decrease) and 1.2 million (13.6% decrease) deaths, respectively. 
 
Increased PCV coverage and decreased disease incidence resulted in reductions in cumulative 
first-line treatments for pneumococcal diseases by 5.1% in the scaled scenario and 8.3% in the 
accelerated scenario. At current levels of PCV coverage, direct costs of first-line treatment for 
pneumococcal diseases in China was estimated at $580,000 in Year 1, increasing yearly to $1.2 
million by Year 5. The scaled scenario reduced direct costs of first-line treatment to $570,000 in 
Year 1 and $960,000 in Year 5 (1.02% to 18.95% reduction). The accelerated scenario further 
reduced direct costs of first-line treatment to $560,000 in Year 1 and $890,000 in Year 5 (2.19% 
to 24.60% reduction). Caretaker productivity losses related to first-line treatment reduced by 
$803 million (6.0% reduction) and $1.3 billion (9.7% reduction) in scaled and accelerated 
scenarios, respectively. Average annual first-line treatment cost savings per child including 
care-taker productivity losses reduced by $3.80 (6% decrease) and $6.15 (9.7% decrease) for 
scaled and accelerated scenarios, respectively.  
 
The AMR-related value of PCV vaccines are presented in Table 3. Based on China’s current 
PCV coverage, we simulated that resistance for penicillin, amoxicillin, and 3rd generation 
cephalosporins would increase by 10.7%, 26.1%, 11.7%, respectively over 5 years. Compared 
to the status quo, the scaled scenario significantly reduced resistance for penicillin, amoxicillin, 
and 3rd generation cephalosporins by 1.7%, 19.2%, and 14.9%, respectively. In the accelerated 
scenario, resistance for penicillin, amoxicillin, and 3rd generation cephalosporins reduced further 
by 2.9%, 30.0%, and 23.4%, respectively. In all three scenarios no significant change in AMR 
ratio was observed for meropenem, likely due to low incidence of pneumococcal meningitis 
resulting in low utilization of the antibiotic.  
 
PCV vaccinations resulted in fewer first-line antibiotic treatment failures for pneumococcal 
pneumonia, meningitis, and AOM at 46.4 million treatment failures over 5 years. The scaled and 
accelerated scenarios decreased treatment failures by 4.1 million (8.8% decrease) and 6.6 
million (14.3% decrease) over 5 years, respectively. Under current PCV coverage, wasted direct 
costs of first-line antibiotics that led to treatment failures were estimated at $4.3 million, growing 
from $580 million in Year 1 to $1.2 million in Year 5. These wasted costs of ineffective treatment 
were reduced by 11% ($450 million) in scaled and 17% ($730 million) in accelerated scenarios.  
 
PCV vaccinations brought AMR benefits for second-line treatment cost savings for 
pneumococcal disease in China. While we estimated direct medical and non-medical costs at 
$1.79 million in Year 1 increasing to $2.74 million by Year 5 under current PCV coverage, the 
scaled scenario reduced second-line treatment costs by $200,000 in Year 1 to $450,000 in Year 
5 (1.00% to 16.63% reduction). The accelerated scenario further reduced these costs by 
$400,000 in Year 1 and $57,000 in Year 5 compared to status quo (2.12% to 20.70% reduction). 
Caretaker productivity losses for second-line treatment reduced by $509 million (8.9% 
reduction) and $825 million (14.4% reduction) in the scaled and accelerated scenarios, 
respectively. Annual cost savings in second-line treatments were also observed at $2.31 (8.9% 
decrease) and $3.75 (14.4% decrease) per child for scaled and accelerated scenarios, 
respectively.  
 
Overall AMR-related costs for pediatric pneumococcal treatment in China was estimated at 
$34.63 billion over 5 years under current PCV coverage. Increase in PCV coverage would 
reduce AMR-related costs by $2.76 billion (8.0% decrease) and $4.5 billion (12.9% decrease) 
over 5 years in scaled and accelerated coverage scenarios, respectively. Moreover, this did not 
include AMR-related productivity losses due to death and disability, which were estimated at 
$27.7 billion based on current PCV coverage, and reduced by $3.5 billion (12.6% decrease) and 




This study is the first to demonstrate the broader economic value of pneumococcal vaccination 
in slowing the development of AMR in China. We show that increased PCV coverage not only 
reduces the disease burden, but also provides AMR benefits including lower AMR ratios, 
reduced treatment failures, averted second-line therapies and cost savings from ineffective or 
unnecessary treatments. AMR-related costs that could be averted by increased PCV coverage 
in China ranged in the billions of US dollars over 5 years.  
 
The AMR benefits of vaccines are essential to incorporate in valuation of vaccines to drive 
appropriate levels of investment. Economic evaluations of vaccinations have not traditionally 
incorporated the AMR benefits of vaccines, having focused on a narrower set of benefits (1, 5). 
Our results suggest that the pneumococcal vaccine has been undervalued by not taking this 
benefit into account, which could affect decision makers’ willingness to invest in this newer 
vaccine. By contributing to slowing the pace of AMR, the pneumococcal vaccine not only saves 
lives but also adds to global efforts to combat AMR.       
 
Our findings demonstrate that introducing PCV in China’s EPI program would not only save 
lives but also bring wider societal benefits by reducing antibiotic utilization, averting treatment 
failures, and saving costs due to AMR. Since pneumococcal vaccination is currently not 
mandated by the Chinese government, it is highly expensive and coverage is very low (4.7%) 
(12). Interested parents must pay out-of-pocket for their children to receive PCV at select 
hospitals with prices around $130 per dose (71). As the vaccine is recommended to be given in 
a series of four doses for children at 2 months, 4 months, 6 months, and 12-15 months of age, 
this comes to a costly total of $520, deterring parents from vaccinating their children and/or 
receiving the full course of the vaccine. Including PCV in the EPI schedule would make the 
vaccine affordable and accessible to the population, allowing China to quickly scale up PCV 
coverage similar to our accelerated scenario. High PCV coverage can trigger herd immunity, 
providing protection from pneumococcal diseases even among those who are not vaccinated. 
Moreover, the large forecasted demand could provide China with the bargaining power to 
negotiate down the vaccine price or manufacture its own PCV vaccine to curb vaccine costs. 
Some Chinese companies are currently conducting research to develop a pneumococcal 
vaccine, which may contribute to these efforts in the long-run (72).  
 
Vaccination is not the only solution to combatting the threat of AMR. The Chinese government 
has made gradual improvements in antimicrobial stewardship, including recent revisions to 
antibiotic use guidelines and enforcement of stricter regulations (73). In 2012, the Chinese 
government passed a law “Administrative Measures for the Clinical Use of Antibacterial Drugs,” 
which strengthened the management and regulation of clinical uses of antibacterial drugs. A 
recent study conducted in primary care institutions in Hubei province showed that antimicrobial 
stewardship interventions can reduce the cost and volume of antibiotic procurement (74).   
 
Our findings are consistent with previous studies on AMR and PCV in China. A 2006 study 
found that China had a faster growth rate of resistance compared to Kuwait and the United 
States, with 22% average AMR growth in China between 1994 and 2000 (75). Our study 
simulated AMR growth by 11% to 26% among 3 commonly used antibiotics over 5 years. A 
2016 study estimated that introduction of PCV in China would decrease cases of AOM by 
10.0% and cases of pneumococcal pneumonia by 15.3%, which is similar to our results in the 
accelerated scenario (76). 
 
One of the other benefits of this study is the development of the DREAMR agent-based model 
to be able to dynamically simulate AMR accumulation. We found that resistance against 
meropenem decreased in our simulation even in the status quo scenario, which is likely due to 
the combined effect of low utilization of this antibiotic to treat pneumococcal diseases and high 
fitness cost of resistant bacteria. As the incidence of pneumococcal meningitis is low, 
meropenem was rarely utilized in our model. As resistant bacteria are less fit to compete for 
survival, we observed a reduction in the AMR ratio over time (60). While these results are 
specific to antibiotic utilization for pediatric pneumococcal diseases in China, the DREAMR 
model could be used to examine the impact of increased PCV coverage on AMR accumulation 
across various countries utilizing different antibiotics.  
 
This study has a number of limitations to note. First, model results are limited by the quality and 
availability of data. Systematic national surveillance data for SP was not available for China, and 
data on rare cases of pneumococcal meningitis were especially difficult to find. Data were also 
limited on inpatient distribution of patients at different health facilities. We obtained model inputs 
from Chinese studies to the greatest extent possible, including literature written in both English 
and Chinese languages. Second, the model was not able to account for within country 
heterogeneity, including large disparities across provinces within China. Using available data, 
we gathered inputs for both urban and rural locations to account for as much variations as 
possible. Third, this study focused on antibiotic use for pediatric pneumococcal diseases, which 
is a limited fraction of overall antibiotic utilization. AMR ratios may be different when also 
considering utilization of antibiotics across other conditions and age groups. Fourth, the current 
model does not incorporate treatment adherence, serotype replacement, or other rarer diseases 
associated with SP. Greater data availability in these areas would facilitate model upgrades to 
examine additional impact. Finally, this study focused on human use of antibiotics, without 
incorporating animal agriculture use. Further research should be conducted taking a One Health 
approach to examine antibiotic utilization across human and animal sectors.  
 
As AMR poses a serious threat to healthcare, the benefit of vaccination in hindering AMR 
progression needs to be reevaluated. This study illustrates the AMR benefits of pneumococcal 
vaccination in China, including reduction in treatment failures and large cost savings. Given the 
sizable pneumococcal disease burden, low PCV coverage, and high antibiotic use, our research 
reveals the significant AMR-related value of introducing PCV in China’s national immunization 
program. These results are useful for governments, partners such as the Bill and Melinda Gates 
Foundation, Gavi (the Vaccine Alliance), UNICEF, and the World Health Organization, as well 
as the vaccine and AMR communities. It contributes to global vaccination and AMR goals in 
addition to supporting the United Nations Sustainable Development Goals (SGDs) and the 
Global Health Security Agenda (GHSA) (77). The AMR benefit of vaccines should be further 
examined to ensure adequate commitments and investments are made for vaccines to not only 
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Table 1: Vaccine Input Parameters of the DREAMR Model 
Parameter variable Unit Value Standard error or uncertainty range Source 
Demographics     
   Total population (2015)  Thousands 1397028.
6 - 
United Nations [(19)] 
   Population, age 0 - 4 (2015) Thousands 85884.7 - United Nations [(19)] 
   Urban population (2017) % 58.0 - United Nations [(26)] 
   Rural population (2017) % 42.0 - United Nations [(26)] 
   Life expectancy at birth (2017) USD 76.4 - United Nations [(70)] 
   GDP per capita (2016) Years 8827.0 - World Bank [(67)] 
     
Epidemiology     
   S. Pneumoniae* colonization rate  % 24.5 19.7-29.4 Wang et al. [(54)] 
     
   Pneumonia     
      Incidence rate age 0-<2 outpatient Cases/100000 2165 1624-2706 Shen et al. [(25)] 
      Incidence rate age 2-<5 outpatient Cases/100000 2238 1679-2798 Shen et al. [(25)] 
      Incidence rate age 0-<2 inpatient Cases/100000 14857 3929-25784 Shen et al. [(25)] 
      Incidence rate age 2-<5 inpatient Cases/100000 14059 1743-26375 Shen et al. [(25)] 
      Case fatality rate % 4.1 - Chen et al. [(62)] 
      Number of cases Cases 260768 113000–582382 Chen et al. [(62)] 
      Number of deaths Cases 10703 4638–23904 Chen et al. [(62)] 
     
   Meningitis     
      Incidence rate 0-<2 Cases/100000 1.3 0.9-1.6 Shen et al. [(25)] 
      Incidence rate 2-<5 Cases/100000 0.6 0-0.7 Shen et al. [(25)] 
      Case fatality rate % 8.3 - Chen et al. [(62)] 
      Number of cases Cases 902 114-4463 Chen et al. [(62)] 
      Number of deaths Cases 75 9-370 Chen et al. [(62)] 
      Hospitalization rate % 100.0 - Assumption 
     
   Acute otitis media     
      Incidence rate 0-<2 (mild) Cases/100000 10678 8009-13348 Shen et al. [(25)] 
      Incidence rate 2-<5 (mild) Cases/100000 10678 8009-13348 Shen et al. [(25)] 
      Incidence rate 0-<2 (severe) Cases/100000 3891 2918-4864 Shen et al. [(25)] 
      Incidence rate 2-<5 (severe) Cases/100000 3891 2918-4864 Shen et al. [(25)] 
      Hospitalization rate % 0.0%  Assumption 
      Clinical resolution rate - amoxicillin % 92.8%  Saux et al. [(32)] 
      Clinical resolution rate – placebo % 84.2%  Saux et al. [(32)] 
      hearing loss  Cases/10000 22.8  Monasta et al. [(63)] 
     
Vaccine characteristics     
   Vaccine effectiveness %    
      Pneumonia 0-<2 % 22 - Shen et al. [(25)] 
      Pneumonia 2-4 % 17 - Shen et al. [(25)] 
      Meningitis 0-<2 % 64 - Shen et al. [(25)] 
      Meningitis 2-4 % 64 - Shen et al. [(25)] 
      AOM <12 months % 22 - Blank et al. [(23)] 
      AOM  12-23 months % 27 - Blank et al. [(23)] 
      AOM  24-59 months % 0 - Blank et al. [(23)] 
   PCV coverage rate 2014     
      2014 % 4.7 - Yuan et al. [(12)] 
          
Careseeking %    
   Urban % 84.4 - Calculated [(27)] 
   Rural % 83.1 - Calculated [(28)]  
   Self-medicate - urban % 14.1 - NHFPC [(30)] 
   Self-medicate - rural % 14.4 - NHFPC [(30)] 
   Did not seek any care - urban % 1.4 - NHFPC [(30)] 
   Did not seek any care - rural % 2.4 - NHFPC [(30)] 
   Mortality rate odds ratio (non-
seeking vs seeking care) 
OR  7.6 3.77-15.1 Reyes et al. [(31)] 
     
Health facility     
   Outpatient-Urban     
      Not reported % 3.5 - Li et al. [(29)] 
      Municipal level % 89.5 - Li et al. [(29)] 
      County level % 7.0 - Li et al. [(29)] 
      Township or village level % 0 - Li et al. [(29)] 
      Private clinic % 0 - Li et al. [(29)] 
   Outpatient-Rural     
      Not reported % 15.6 - Li et al. [(29)] 
      Municipal level % 39.7 - Li et al. [(29)] 
      County level % 10.1 - Li et al. [(29)] 
      Township or village level % 17.1 - Li et al. [(29)] 
      Private clinic % 17.6 - Li et al. [(29)] 
   Inpatient-Urban     
      Not reported % 3.5 - Calculated [(29)] 
      Municipal level % 89.5 - Calculated [(29)] 
      County level % 7.0 - Calculated [(29)] 
      Township or village level % 0 - Calculated [(29)] 
      Private clinic % 0 - Calculated [(29)] 
   Inpatient-Rural     
      Not reported % 15.6 - Calculated [(29)] 
      Municipal level % 45.6 - Calculated. [(29)] 
      County level % 15.9 - Calculated [(29)] 
      Township or village level % 22.9 - Calculated [(29)] 
      Private clinic % 0 - Calculated [(29)] 
     
   Inpatient treatment     
      Not reported % 1.4%  Calculated [(29)] 
      Municipal level % 1.5%  Calculated [(29)] 
      County level % 2.0%  Calculated [(29)] 
      Township or village level % 1.8%  Calculated [(29)] 
      Private clinic % 0.0%  Calculated [(29)] 
     
   Treatment length      
      Treatment follow-up Days 3 - Bradley et al. [(33)] 
      Pneumonia - inpatient Days 7.1 4.2-10 Zhang et al. [(39)] 
      Pneumonia - outpatient Days 7 - Assumption 
      Meningitis Days 21 - Li et al. [(38)] 
      Acute otitis media Days 7 - Committee  [(37)] 
     
Antibiotics     
   Resistance     
      Penicillin G % 53.8 - Li et al. [(38)] 
      Amoxicillin % 8.1 - Lyu et al. [(42)] 
      3rd generation cephalosporins % 20.8 - Lyu et al. [(42)] 
      Meropenem % 36.0 - Liu et al. [(43)] 
     
   Utilization     
      Pneumonia       
         Penicillin G % 31.5  Li, Ruimei. [(40)] 
         Amoxicillin % 39.4  Adjusted [(40)] 
         3rd gen cephalosporin % 29.0  Li, Ruimei.  [(40)] 
      Meningitis      
         Meropenem % 100  Adjusted [(41)] 
      Acute Otitis Media     
         Penicillin G % 44.4  Calculated [(40)] 
         Amoxicillin % 55.6  Calculated [(40)] 
Distribution of Costs     
   Type of cost     
      Direct medical cost - outpatient % 62.8 - Li et al. [(29)] 
      Direct medical cost - inpatient % 88.3 - Li et al. [(29)] 
     
   Mean medical expenditure by type of 
health facility 
    
      Outpatient     
         Municipal USD 174.7 - [(29)] [(66)] 
         County USD 126.9 - [(29)] [(66)] 
         Township or Village USD 75.1 - [(29)] [(66)] 
      Inpatient     
         Municipal USD 783.3 - Ma et al. [(66)] 
         County USD 568.8 - Ma et al. [(66)] 
         Township or Village USD 336.7 - Ma et al. [(66)] 















Table 2: Health and Economic Outcomes of PCV13  
 


















Cumulative disease cases        
   Pneumococcal pneumonia, n   70,790,290  -5,711,125 -8.07% <0.01 -9,444,681 -13.34% <0.01 
   Pneumococcal meningitis, n  2,774  -701 -25.27% <0.01 -1,074 -38.73% <0.01 
   Pneumococcal AOM, n  62,220,967  -2,898,247 -4.66% <0.01 -4,487,762 -7.21% <0.01 
Cumulative adverse health outcomes        
   Overall death, n  1,355,635   -109,733 -8.09% <0.01 -183,642 -13.55% <0.01 
   Disability, n  9,485   -428 -4.51% <0.01 -725 -7.64% 0.068 
Treatment behavior        
   Cumulative first line treatments, n  71,640,310 -3,678,303 -5.13% <0.01 -5,951,186 -8.31% <0.01 
   Cumulative second line treatments, n  46,545,018 -4,113,850 -8.84% <0.01 -6,647,389 -14.28% <0.01 
Average defined daily dose, per 1000 patient days 5.84 -0.40 -6.89% <0.01 0 0.01% 0.85 












Table 3: AMR Benefits from Increasing Pneumococcal Vaccination in China 
 













(Accel. vs SQ) 
P 
Value 
Incremental change in resistance        
   Penicillin, % 10.74 -0.19 -1.74% <0.01 -0.31 -2.87% <0.01 
   Amoxicillin, % 26.11 -5.01 -19.19% <0.01 -7.83 -29.97% <0.01 
   3rd generation cephalosporins, % 11.72 -1.74 -14.87% <0.01 -2.74 -23.35% <0.01 
   Meropenem, % -3.81 0.00 0.01% 0.85 0.00 0.01% 0.94 
Treatment failures        
   Cumulative treatment failures, n  46,546,169  -4,114,085 -8.84% <0.01 -0.65 -11.16% <0.01 
      Treatment failure (pneumonia), n  24,829,955  -2,624,764 -10.57% <0.01 -6,647,750 -14.28% <0.01 
      Treatment failure (meningitis), n  921  -222 -24.11% <0.01 -4,269,777 -17.20% <0.01 
      Treatment failure (AOM), n  21,806,207  -1,503,290 -6.89% <0.01 -344 -37.35% <0.01 
   Proportion of treatments resulting in failures, % 39.38% -0.95% -2.40% <0.01 -2,401,860 -11.01% <0.01 
Average annual costs per child in first-line 
treatment due to resistance 
       
   Overall costs, USD  10.25  -1.14 -11.08% <0.01 -1.83 -17.86% <0.01 
   Direct medical costs, USD  3.17  -0.35 -11.13% <0.01 -0.57 -17.95% <0.01 
   Direct non-medical costs, USD  1.81  -0.20 -11.05% <0.01 -0.32 -17.81% <0.01 
   Productivity losses for caretaker, USD 5.27  -0.58 -11.06% <0.01 -0.94 -17.82% <0.01 
Average annual costs per child in second-line 
treatment 
       
   Overall costs, USD  26.03  -2.31 -8.89% <0.01 -3.75 -14.39% <0.01 
   Direct medical costs, USD 8.05  -0.72 -8.94% <0.01 -1.17 -14.48% <0.01 
   Direct non-medical costs, USD  4.60  -0.41 -8.86% <0.01 -0.66 -14.34% <0.01 
   Productivity losses for caretaker, USD  13.38  -1.19 -8.87% <0.01 -1.92 -14.35% <0.01 
Direct costs due to resistance in first line 
treatment, USD 
        
   Year 1 576,860,426 -5,874,112 -1.02% <0.01 -12,661,690 -2.19% <0.01 
   Year 2 693,525,228 -28,530,502 -4.11% <0.01 -61,917,227 -8.93% <0.01 
   Year 3 823,705,607 -67,170,292 -8.15% <0.01 -149,617,478 -18.16% <0.01 
   Year 4 984,679,043 -126,174,598 -12.81% <0.01 -213,847,995 -21.72% <0.01 
   Year 5 1,180,908,773 -223,778,118 -18.95% <0.01 -290,540,204 -24.60% <0.01 
  Productivity losses for caretaker, USD 5,296,973,655 -435,816,652 -8.23% <0.01 -705,814,816 -13.32% <0.01 
Direct costs due to resistance in second line 
treatment, USD 
       
   Year 1 1,788,064,766 -17,666,916 -0.99% <0.01 -37,819,714 -2.12% <0.01 
   Year 2 1,990,245,181 -77,405,255 -3.89% <0.01 -168,397,355 -8.46% <0.01 
   Year 3 2,203,451,649 -164,317,126 -7.46% <0.01 -369,441,108 -16.77% <0.01 
   Year 4 2,452,706,535 -278,205,047 -11.34% <0.01 -464,963,215 -18.96% <0.01 
   Year 5 2,742,489,542 -455,990,189 -16.63% <0.01 -567,758,255 -20.70% <0.01 
   Productivity losses for caretaker, USD 5,745,659,142 -509,482,402 -8.87% <0.01 -824,540,146 -14.35% <0.01 
Cumulative costs due to resistance, USD 26,479,269,546 -2,390,411,209 -9.03% <0.01 -3,867,319,202 -14.61% <0.01 
Projected productivity losses from 
death/disability due to resistance, USD 
27,722,050,208 -3,504,994,360 -12.64% <0.01 -5,692,819,084 -20.54% <0.01 
AOM; acute otitis media, USD; United States dollar, SQ; status quo. Point estimates were derived from taking averages across 5,000 base case simulations. 
Productivity losses are calculated from 15 years of age until death for all affected individuals (DALY weight of 1 for death and DALY weight of 0.158 for disability)





Figure 2: AMR-related Cost Savings From Increased PCV Coverage in China 
 
 
AMR: Antimicrobial resistance; PCV: Pneumococcal conjugate vaccine; USD: United States Dollars. 
* Scaled scenario linearly increased PCV coverage from 4.7% to 99% over five years.  
** Accelerated scenario increased PCV coverage linearly from 4.7% to 85% in the first two years, and to 
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